A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

Clinical trial NCT06331299 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06331299
Sponsor: UroGen Pharma Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Bladder Cancer Urothelial Carcinoma Urothelial Carcinoma Bladder

Start date: 2024-08-29
Primary completion: 2025-09-11
Enrollment: 99

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.